Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
  • Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders
     
  • Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilars
     
  • Sandoz launched initiative to support improved healthcare access, equity and sustainability

Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …

/by
Sandoz appoints new Board representative to global AMR Industry Alliance
  • Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)
  • The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMR
  • Sandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced …
/by
Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
  • Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2
  • Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new cases are diagnosed annually3
  • Sandoz is committed to developing and providing patient access to high-quality, more affordable generic medicines, especially in areas of high unmet need

Princeton, May 12, 2022 — Sandoz, a global leader in …

/by